Funding Rounds
Idrx August 2024 Series B Funding Round
IDRxIDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today’s precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy.
Summary
Stage: Series B
Raised Amount: $120.00M
Raised Date: 2024-08-07